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Abstract
Background: Appropriate empiric therapy, antibiotic therapy with in vitro activity to the infecting organism given prior to
confirmed culture results, may improve Staphylococcus aureus outcomes. We aimed to measure the clinical impact of
appropriate empiric antibiotic therapy on mortality, while statistically adjusting for comorbidities, severity of illness and
presence of virulence factors in the infecting strain.
Methodology: We conducted a retrospective cohort study of adult patients admitted to a tertiary-care facility from January
1, 2003 to June 30, 2007, who had S. aureus bacteremia. Time to appropriate therapy was measured from blood culture
collection to the receipt of antibiotics with in vitro activity to the infecting organism. Cox proportional hazard models were
used to measure the association between receipt of appropriate empiric therapy and in-hospital mortality, statistically
adjusting for patient and pathogen characteristics.
Principal Findings: Among 814 admissions, 537 (66%) received appropriate empiric therapy. Those who received
appropriate empiric therapy had a higher hazard of 30-day in-hospital mortality (Hazard Ratio (HR): 1.52; 95% confidence
interval (CI): 0.99, 2.34). A longer time to appropriate therapy was protective against mortality (HR: 0.79; 95% CI: 0.60, 1.03)
except among the healthiest quartile of patients (HR: 1.44; 95% CI: 0.66, 3.15).
Conclusions/Significance: Appropriate empiric therapy was not associated with decreased mortality in patients with S.
aureus bacteremia except in the least ill patients. Initial broad antibiotic selection may not be widely beneficial.
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Introduction
Staphylococcus aureus bacteremia is associated with considerable
excess morbidity, mortality, and healthcare costs [1,2]. The
current paradigm for the treatment of suspected invasive bacterial
infections, including for S. aureus bacteremia, is to prescribe
antibiotics as quickly as possible in order to prevent mortality [3].
Yet, optimal treatment strategies for S. aureus bacteremia are not
precisely defined. Antibiotic therapy with in vitro activity to the
infecting organism given prior to known culture results, known as
appropriate empiric antibiotic therapy, may improve patient
outcomes [4–10]. On the other hand, over-prescription of
antibiotics may lead to an increase in adverse reactions, higher
medical costs, and increased antibiotic selection pressure [10].
Previous studies of the association between appropriate
antibiotic therapy for S. aureus infections and mortality, have
demonstrated conflicting results [4–16]. The differences in these
results may be due to different methods of measuring exposures
and outcomes, failure to control for necessary confounders such as
severity of illness, or incorrectly statistically adjusting for variables
which are part of the causal pathway between infection and
mortality [17–18]. This study aimed to assess the independent
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11432association between receipt of appropriate empiric therapy for S.
aureus bacteremia and mortality in a large cohort, while statistically
adjusting for patient and pathogen characteristics.
Methods
Ethics
This study was approved by the institutional review board of the
University of Maryland, Baltimore. A waiver of consent was
granted given the retrospective nature of the project.
Study Design and Patient Population
This retrospective cohort study included all adult admissions to
University of Maryland Medical Center (UMMC), a tertiary care
facility, between January 1, 2003 and June 30, 2007, who had a
positive blood culture for S. aureus. Each admission was handled as
an independent event and therefore patients may have been
included in the study more than once. Eligible patients were
identified using a relational database that contains medical,
pharmaceutical and microbiologic data. These data have been
validated in previous studies and have positive and negative
predictive values in excess of 99 percent when compared to paper
medical records [18–23]. Additional variables that were not
available in the relational database were collected by a research
nurse via chart review.
Variable Definitions
Antibiotic therapy was defined as appropriate if the S. aureus
isolate from the blood culture was susceptible to that antibiotic in
vitro. The timing of appropriate therapy was measured in three
different ways. First, empiric antibiotic therapy was defined as
receipt of any antibiotic during the period 24 hours before to
24 hours after the culture collection. If the blood culture was
collected within 24 hours of hospital admission, the empiric
therapy window began at the time of admission. Second, time to
appropriate therapy was measured as the time from culture
collection to the time appropriate therapy was first received no
matter if the appropriate therapy was given empirically or
definitively. Third, receipt of any appropriate therapy was a
dichotomous variable defined as receipt of appropriate therapy at
any time from culture collection to death or discharge.
The outcome of interest, 30-day in-hospital mortality, was
measured as mortality occurring in the hospital during the time
period from culture collection to 30 days after culture collection.
Severity of illness was measured for 24 hours before the time the
culture was obtained using the modified Acute Physiology Score
(APS). If the blood culture was obtained within 24 hours of
hospital admission, APS at the time of admission was calculated.
The modified APS is based on the Acute Physiology and Chronic
Health Evaluation (APACHE) III score and was measured for all
patients in the cohort [24]. Since the APACHE III was originally
designed for use in intensive care unit (ICU) patients, the score has
been modified by excluding variables that are not applicable to
this study population [21,24,25]. The Chronic Disease Score, an
aggregate measure of comorbid conditions, which has been
validated for use in studies on methicillin-resistant S. aureus
(CDS-MRSA), was calculated using in-patient pharmacy order
records [19]. The CDS-MRSA was calculated by assigning a
weighted value to medications prescribed for four comorbid
conditions (diabetes, peptic ulcers, respiratory illness and kidney
disease) within the first 24 hours of admission [19]. Prior history of
methicillin-resistant S. aureus (MRSA) colonization or infection was
measured using infection control documentation of positive
surveillance or clinical cultures for MRSA during any previous
admission to UMMC.
In 2004, the UMMC clinical laboratory instituted the use of a
peptide nucleic acid fluorescence in situ hybridization (PNA FISH)
(AdvanDx, Woburn, MA) assay which is able to identify the S.
aureus 16S rRNA from blood cultures approximately three hours
after the identification of Gram-positive cocci in clusters [26]. The
goal of this assay is to reduce the amount of time necessary to
detect S. aureus in a blood culture [26]. The institution of the S.
aureus PNA FISH assay was statistically adjusted for in our analyses
because a shorter time to identification of S. aureus could reduce
the time to appropriate definitive therapy.
Laboratory methods
All S. aureus positive blood cultures during this study period were
stored in the clinical laboratory at 280uC. Identification of
Staphylococcus aureus was determined by gram stain and colony
morphology, catalase and coagulase positive reactions or by the S.
aureus PNA FISH assay. Antimicrobial susceptibility profiles were
determined according to Clinical and Laboratory Standards
Institute (CLSI) guidelines [27]. Susceptibility testing was
performed by the hospital clinical laboratory for erythromycin,
clindamycin (including the disk diffusion test for inducible
resistance), sulfamethoxazole and trimethroprim, ampicillin and
sulbactam, oxacillin, tetracycline, ampicillin, cephalothin, penicil-
lin, rifampin, gentamicin, gatifoxacin, moxifloxacin, and vanco-
mycin. Vancomycin, daptomycin, and linezolid minimum inhib-
itory concentrations (MICs) were measured using the
microdilution Epsilometer test (Etest) (AB BIODISK, Solna,
Sweden; bioMe ´rieux, Durham, NC) according to manufacturer’s
instructions and following CLSI guidelines [27,28].
Polymerase chain reaction (PCR) was used to determine the
presence of the Panton-Valentine leukocidin (PVL) and arginine
catabolic mobile element (ACME) genes [29,30]. The polymor-
phic X region of the Staphylococcal protein A (spa) gene was
sequenced and typed according to previously described procedures
[31,32]. The USA300 clone was defined as any S. aureus isolates
that was of spa-type motif MBQBLO, PVL-positive, and ACME-
positive as previously validated [33].
Statistical Methods
Bivariate associations were assessed using the chi-square test or
Fisher’s exact test for categorical variables and the Students t-test
or the Wilcoxon Rank Sum test for continuous variables. Cox
proportional hazard models were fit to measure the hazard ratios
(HRs) and 95% confidence intervals (CIs) for the associations of
interest.
All variables that were significant in the bivariable analysis
(a,0.1) were included in the initial (full) multivariate Cox
proportional hazard model. Variables that were not significantly
associated with the outcome (a.0.05) were removed from the full
multivariate modelinsuccession.Each oftheremoved variableswas
then reinserted into the model to assess whether the variable altered
the regression coefficient of the primary exposure variable by
greater than 20 percent. If so, that variable was included in the
model. Appropriate empiric therapy or time to appropriate therapy
was included in each model irrespective of its statistical significance.
A priori we chose the following variables as biologically important:
the main predictor variables (either appropriate empiric therapy or
time to appropriate therapy), methicillin resistance, age and severity
of illness score. These variables were included in each model
irrespective of their statistical significance. In the survival analysis,
time to appropriate therapy was treated as a time-varying covariate,
which allows for changing hazards over time. Interaction terms
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variables.Inasub-analysis,thecohortwasstratifiedintoquartilesby
severity of illness to determine whether severity of illness modified
the risk of mortality among patients with bloodstream infections as
hasbeenpreviouslydemonstrated [34].Allanalyseswereperformed
using SAS software (SAS Institute, Cary, NC) version 9.1. Further
details of the statistical analysis can be found in Appendix S1.
Results
Overall, there were 1050 episodes of S. aureus bacteremia during
the study period. Of these, 814 (78%) had S. aureus blood isolates
saved and identified for inclusion and molecular analysis.
Excluded cases that were missing a S. aureus blood isolate did
not differ significantly from included cases with regard to
methicillin resistance, receipt of appropriate empiric therapy or
mortality (data not shown). Among the 814 patients included in
the study, 537 (66%) received appropriate empiric therapy and
109 (13%) patients died within 30 days of culture collection.
Patients who received appropriate empiric therapy were more
likely to be infected with methicillin-susceptible S. aureus (MSSA),
to have a polymicrobial infection, to have a higher severity of
illness score, to be an injection drug user, to be previously
hospitalized in the past year and to have renal disease (p,0.05).
Patients who received inappropriate empiric therapy were more
likely to have a longer length of stay from admission to culture
collection, to be admitted to the ICU before culture collection and
to be mechanically ventilated before culture collection (p,0.05)
(Table 1). Of those that received appropriate empiric therapy,
75% received vancomycin, 8% received nafcillin or a first
generation cephalosporin, 7% received vancomycin and nafcillin
or vancomycin and a first generation cephalosporin, 11% received
piperacillin/tazobactam, 4% received a third generation cephalo-
sporin, 1% received trimethoprim/sulfamethoxazole, 1% received
clindamycin, 1% received daptomycin, 4% received linezolid, and
less than 1% received any other antibiotic.
Patients who died within 30 days of hospitalization were more
likely to be older, admitted to the ICU before the culture was
collected, to have higher severity of illness and comorbidity scores,
to have a central venous catheter, and to be mechanically
ventilated before culture collection (p,0.05). Patients who
survived were more likely to have HIV or AIDS, to have been
Table 1. Characteristics of the Study Population Stratified by Appropriateness of Empiric Therapy.
Inappropriate Empiric
Therapy (n=277; 34%)
Appropriate Empiric
Therapy (n=537; 66%)
Total
(n=814) P
Age, mean6SD, years 49617 49616 49616 0.82
Female sex 99 (36%) 210 (39%) 309 (38%) 0.35
Year 0.02
2003 85 (31%) 124 (23%) 209 (26%)
2004 68 (25%) 136 (25%) 204 (25%)
2005 47 (17%) 138 (26%) 185(23%)
2006 56 (20%) 94 (18%) 150 (18%)
2007
a 21 (8%) 45 (8%) 66 (8%)
CDS MRSA, median (IQR) 1.0 (0, 2.2) 1.0 (0, 2.1) 1.0 (0, 2.1) 0.93
Diabetes mellitus 31 (11%) 64 (12%) 95 (12%) 0.79
Renal disease 16 (6%) 57 (11%) 73 (9%) 0.02
AIDS 31 (11%) 74 (14%) 105 (13%) 0.32
Malignancy 24 (9%) 56 (10%) 80 (10%) 0.45
BMI, mean6SD, kg/m
2 2767.9 2769.8 2769.2 0.53
Modified APS, median, IQR 15 (8, 25) 18 (9, 30) 17.0 (9.0, 28) ,0.01
Time from admission to culture, median, IQR, days 0.94 (0.07, 7.5) 0.17 (0, 3.7) 0.27 (0, 5.0) ,0.01
Prior history of MRSA 33 (12%) 95 (18%) 128 (16%) 0.03
Admitted to ICU prior to culture collection 109 (39%) 138 (26%) 247 (30%) ,0.01
Hospitalized in past year 107 (39%) 249 (46%) 356 (44%) 0.03
Injection Drug Use 71 (26%) 180 (34%) 251 (31%) 0.02
Mechanical ventilation prior to 24 hours before culture collection 70 (25%) 90 (17%) 160 (20%) ,0.01
Infectious disease physician consult624 hours of culture collection 18 (7%) 57 (11%) 75 (9%) 0.05
Presence of central venous catheter before culture collection 135 (49%) 301 (56%) 436 (54%) 0.05
Polymicrobial Infection 22 (8%) 67 (12%) 89 (11%) 0.05
Methicillin resistance 196 (71%) 292 (54%) 488 (60%) ,0.01
Vancomycin MIC, mean6SD, mg/ml 1.560.4 1.560.6 1.560.6 0.52
USA 300 64 (23%) 126 (23%) 190 (23%) 0.91
Note. Data are no. (%) of admissions, unless otherwise indicated. IQR, interquartile range; MRSA, methicillin-resistant Staphylococcus aureus; ICU, intensive care unit; SD,
standard deviation; MIC, minimum inhibitory concentration. Polymicrobial infection was defined as more than one microorganism present from the same blood culture.
aOnly the first 6 months of 2007 were assessed.
doi:10.1371/journal.pone.0011432.t001
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the index admission, and to be injection drug users (p,0.05).
Increased vancomycin MIC and the USA300 clone were not
associated with 30-day in-hospital mortality (p=0.79 and 0.28,
respectively) and did not confound the association between
appropriate empiric therapy and mortality.
In the bivariate analysis, appropriate empiric therapy was not
significantly associated with 30-day in-hospital mortality (unadjusted
Hazard Ratio (HR)=1.52; 95% Confidence Interval [CI]: 0.99,
2.34). The results remained similar when this association was
adjusted for severity of illness, methicillin resistance, age, culture
collection at admission, polymicrobial infection and ICU admission
prior to culture collection using a Cox proportional hazards model
(adjustedHR:1.50;95%CI:0.96,2.35)(Table2).Inordertofurther
adjust for residual confounding due to measured differences between
appropriate and inappropriate empiric therapy, a propensity score
for the probability of receipt of appropriate empiric therapy was
created and added to the final Cox proportional hazard model. As
demonstrated in other studies, the addition of a propensity score did
not significantly change the hazard ratio or confidence interval for
the association between appropriate empiric therapy and mortality
(data not shown) [12,16,35].
Among the 774 patients who received appropriate therapy at
any time between culture collection and discharge, the median
time to appropriate therapy was 0.38 days (interquartile range
(IQR): 0.01, 1.22). Time to appropriate therapy was shorter
among patients who were hospitalized in the years following when
the S. aureus PNA FISH assay was instituted (median=0.34 days;
IQR: 0.03, 1.15) compared to those hospitalized in earlier years
(median=0.59 days; IQR: 0.01, 1.43) although this difference
only approached statistical significance, p=0.06. Also, patients
infected with MRSA had longer times to appropriate therapy
(median=0.69 days; IQR: 0.07, 1.49) compared to patients
infected with MSSA (median=0.22 days; 0.00, 0.93).
A longer time to appropriate therapy was protective against
mortality, although not significantly so (adjusted per-day HR:
0.79; 95% CI: 0.60, 1.03), after statistically adjusting for severity of
illness, age, methicillin resistance, prior history of MRSA, culture
collection after the S. aureus PNA FISH assay was instituted, and
admission to the ICU before culture collection (Table 3). When
the cohort was stratified into quartiles by severity of illness, a
longer time to appropriate therapy was a risk factor for mortality
among the healthiest quartile of patients but was protective against
mortality for the other quartiles (Table 3).
Before death or discharge, 774 (95%) patients received any
appropriate (empiric or definitive) therapy and 40 (5%) never
received appropriate therapy. Thirteen percent of the patients who
received any appropriate therapy and 18% of the patients who
never received appropriate therapy died within 30 days of
hospitalization (p=0.43). Those that received any appropriate
therapy were significantly less likely to die (adjusted HR: 0.25;
95% CI: 0.10, 0.58) compared to those who never received
appropriate therapy after statistically adjusting for severity of
illness, methicillin resistance, age, culture collected within an hour
of admission, polymicrobial infection and admission to the ICU
prior to culture collection (Table 2).
Stratified analyses were performed across numerous clinically
significant strata but did not change the associations between
appropriate empiric therapy or time to appropriate therapy and
mortality. For example, when the association between appropriate
empiric therapy and mortality was stratified by methicillin
resistance, the measures of effect remained similar (relative risk
(RR) among MRSA: 1.68; RR among MSSA: 1.41; Breslow-Day
Test for Homogeneity p-value=0.75). The measures of effect for
the association between appropriate empiric therapy and mortality
did not change when stratified by presence of diabetes (RR among
diabetic patients: 2.26, RR among patients without diabetes: 1.33;
Breslow-Day Test for Homogeneity p-value=0.37), or surgery on
the index admission (RR for surgical patients: 2.71, RR for non-
surgical patients: 1.40; Breslow-Day Test for Homogeneity p-
value=0.52). Additionally, when we stratified the cohort by ICU
admission, a longer time to appropriate therapy was protective
against mortality among both ICU and non-ICU patients (ICU
HR: 0.91; non-ICU HR: 0.74) except among the healthiest
quartile of patients (ICU HR: 1.23; non-ICU HR: 2.28).
Sub-cohort analyses were also performed. When we excluded
patients who only received vancomycin empirically (n=305), we
found a similar association between receipt of appropriate empiric
therapy and mortality (adjusted HR: 1.03; 95% CI: 0.53, 1.97).
Also, when we limited the cohort to include only the first
admission from each patient (n=761) and repeated the Cox
proportional hazard analyses, the magnitude and statistical
significance of the associations of interest remained similar.
Discussion
In this large cohort of patients with S. aureus bacteremia,
appropriate empiric therapy and time to appropriate therapy were
Table 2. Components of the final Cox proportional hazard models.
Characteristic
Adjusted Association between Appropriate
Empiric Therapy and 30-day In-hospital
Mortality HR (95% CI)
Adjusted Association between Receipt
of Any Appropriate Therapy and 30-day
In-hospital Mortality HR (95% CI)
Appropriate Empiric Therapy 1.50 (0.96, 2.35)
Receipt of Any Appropriate Therapy 0.25 (0.10, 0.58)
Severity of Illness
a 1.04 (1.03, 1.05) 1.04 (1.03, 1.05)
Methicillin Resistance 1.28 (0.86, 1.92) 1.20 (0.81, 1.79)
Age
b 1.04 (1.02, 1.05) 1.04 (1.03, 1.05)
Culture collected within 1 hour of admission 1.94 (1.08, 3.50) 2.13 (1.18, 3.84)
Polymicrobial Infection 0.55 (0.30, 1.01) 0.61 (0.33, 1.11)
Admitted to ICU prior to culture collection 2.17 (1.28, 3.68) 2.07 (1.23, 3.50)
aHazard ratios were calculated as per unit increase of the modified APS.
bHazard ratios were calculated as per year increase in age.
doi:10.1371/journal.pone.0011432.t002
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with the lowest underlying severity of illness score. These results
are consistent with previous studies which did not find significant
independent associations between appropriate empiric therapy
and mortality [12–16]. Our study differs from these publications in
that our study had a much larger patient population and we
incorporated characteristics of the infecting pathogen, such as
antibiotic minimum inhibitory concentrations and presence of the
USA300 clone, into the analysis. Two of these smaller studies
assessed the association between inappropriate empiric therapy
and 30-day mortality and found that inappropriate empiric
therapy was protective, although not significantly so, against
mortality [15,16]. A potential explanation for these results is that a
delay in the receipt of appropriate antibiotic therapy may not have
affected the progression of the infection among the patients that
died [12,15]. This hypothesis is supported by the protective effect
of appropriate therapy given at any time against mortality. This
may indicate that the eventual receipt of appropriate antibiotics is
protective against mortality, but the timing of the receipt of
appropriate antibiotics in the initial 24 hours is less important.
Prior study results of a significant association between
appropriate antibiotic therapy and mortality may be due to
different methods of measuring exposures and outcomes, failure to
control for necessary confounders such as severity of illness, or
incorrectly statistically adjusting for variables which are part of the
causal pathway between infection and mortality. Studies by Lodise
et al., Romero-Vivas et al., and Soriano et al. did not differentiate
between empiric and definitive antibiotic therapy [4,6,8].
Therefore, the results of those studies are similar to our finding
that patients who ever received appropriate antibiotic therapy
were less likely to die compared to patients who never received
appropriate antibiotics. Studies by Robinson et al., Leibovici et al.,
and Shorr et al. found that appropriate empiric therapy was
associated with mortality in bivariate analyses but did not control
for variables such as age, severity of illness or underlying
comorbidities which could potentially confound the association
between appropriate empiric therapy and mortality [7,10,11].
Finally, studies by Schramm et al., Soriano et al., and Gomez et al.
controlled for shock, which is part of the causal pathway between
S. aureus bacteremia and mortality [5,8,9]. Differences in results
could also be due to differences in study populations. Some studies
only assessed appropriate empiric therapy for MRSA, some
included all sterile sites of infection and all studies were from
geographically diverse areas which may exhibit differences in
antibiotic prescribing, antibiotic resistance trends and differing
patient populations.
Our finding that a longer time to appropriate therapy was a risk
factor for mortality among the healthiest quartile of patients but
was protective against mortality for the other quartiles indicates
that efforts to prescribe broad-spectrum antibiotics to severely ill
patients may not be beneficial. However, these associations may be
affected by residual confounding by indication. Confounding by
indication occurs when a characteristic is an indication for the
treatment of interest and is a risk factor for the outcome of interest
[36]. As our study showed, severely-ill patients were more likely to
both receive appropriate antibiotics early (most likely in the form
of broad-spectrum antibiotics) and to die compared to less severely
ill patients. Thus, despite our attempts to control for severity of
illness, residual severity of illness may have confounded the
relationship between time to appropriate therapy and mortality.
Alternatively, the effect of time to appropriate antibiotic therapy
on mortality may be greater among less severely ill patients
compared to more severely ill patients. This is supported by Kim
et al. in a study that compared mortality hazards among patients
with and without bloodstream infections, stratified by severity of
illness. That study found a significant difference in mortality
hazards among patients with lower severity of illness scores on
admission (HR: 2.42; 95% CI: 1.70, 3.44) but no difference when
this association was assessed among more severely ill patients (HR:
0.96; 95% CI: 0.76, 1.23). Kim hypothesized that a bloodstream
infection may be of greater consequence among the less severely
ill, while the addition of a bloodstream infection to the number of
life-threatening conditions among severely ill patients does not
considerably decrease their probability of survival [34].
Currently, vancomycin appears to be the drug of choice for
appropriate empiric therapy. However, studies have shown that
vancomycin may be associated with increased S. aureus treatment
failure compared to other antibiotics [37,38]. In this study, the
exclusion of patients who only received vancomycin empirically
did not change the association between appropriate empiric
therapy and mortality.
A limitation of this study is that it was performed at a single
center and therefore these results may not be generalizable outside
of this patient population. This study was also limited by its
observational nature. However, a randomized control trial is not
feasible in this situation because it would be unethical to
randomize patients to receive inappropriate empiric therapy.
Lastly, we were unable to assess whether mortality was due to the
S. aureus bacteremia and not other causes. Thus, our use of 30-day
in-hospital mortality may be an over-estimate of infection-related
mortality. However, 30-day in-hospital mortality has been used
routinely as an outcome in other S. aureus studies [7,39].
Table 3. Survival Analysis Models of Adjusted Association between Time to Appropriate Therapy and 30-day In-hospital Mortality
Stratified by Severity of Illness.
Characteristic
Total Cohort
(N=814)
Quartile 1 Modified
APS,9 (n=195)
HR (95% CI)
Quartile 2 Modified
APS $9 and ,17
(n=208) HR (95% CI)
Quartile 3 Modified
APS $17 and ,28
(n=195) HR (95% CI)
Quartile 4 Modified
APS$28 (n=216)
HR (95% CI)
Time to Appropriate Therapy 0.79 (0.60, 1.03) 1.44 (0.66, 3.15) 0.71 (0.29, 1.74) 0.58 (0.29, 1.15) 0.71 (0.49, 1.02)
Methicillin Resistance 1.32 (0.87, 2.00) 4.62 (0.51, 41.91) 2.19 (0.49, 9.86) 0.61 (0.26, 1.41) 1.55 (0.89, 2.69)
Age 1.04 (1.03, 1.05) 1.04 (0.99, 1.09) 1.03 (0.99, 1.07) 1.02 (0.99, 1.05) 1.03 (1.02, 1.05)
Admitted to ICU prior to culture collection 1.49 (0.98, 2.27) 8.70 (2.01, 37.72) 3.81 (0.89, 16.39) 1.98 (0.83, 4.74) 1.12 (0.67, 1.87)
Time S. aureus PNA FISH Assay in Use 0.80 (0.54, 1.20) 6.40 (0.98, 41.83) 2.85 (0.69, 11.71) 0.33 (0.13, 0.85) 0.80 (0.48, 1.35)
Modified APS 1.04 (1.03, 1.05) – – – –
doi:10.1371/journal.pone.0011432.t003
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expected clinical benefits of the individual patient against the
public health implication of overuse of antibiotics. Appropriate
empiric therapy may reduce adverse outcomes in healthier
patients, but initial broad empiric coverage for S. aureus bacteremia
among severely ill patients may not be beneficial. Therefore,
future efforts should continue to identify casual factors associated
with increased mortality in patients with S. aureus bacteremia.
Supporting Information
Appendix S1 Detailed Statistical Analysis. Detailed Description
of Statistical Analysis
Found at: doi:10.1371/journal.pone.0011432.s001 (0.03 MB
DOC)
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